NASDAQ:PGNY Progyny (PGNY) Stock Forecast, Price & News $34.35 -0.04 (-0.12%) (As of 01:51 PM ET) Add Compare Share Share Today's Range$34.04▼$34.9850-Day Range$33.09▼$42.9052-Week Range$28.03▼$45.98Volume281,184 shsAverage Volume818,048 shsMarket Capitalization$3.28 billionP/E Ratio70.10Dividend YieldN/APrice Target$48.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Progyny MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside41.4% Upside$48.67 Price TargetShort InterestBearish6.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.12Based on 9 Articles This WeekInsider TradingSelling Shares$122.85 M Sold Last QuarterProj. Earnings Growth25.93%From $0.54 to $0.68 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.03 out of 5 starsMedical Sector28th out of 971 stocksMiscellaneous Health & Allied Services, Not Elsewhere Classified Industry1st out of 7 stocks 4.4 Analyst's Opinion Consensus RatingProgyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.67, Progyny has a forecasted upside of 41.4% from its current price of $34.42.Amount of Analyst CoverageProgyny has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.61% of the float of Progyny has been sold short.Short Interest Ratio / Days to CoverProgyny has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Progyny has recently increased by 0.74%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldProgyny does not currently pay a dividend.Dividend GrowthProgyny does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PGNY. Previous Next 3.4 News and Social Media Coverage News SentimentProgyny has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Progyny this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for PGNY on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows9 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $122,853,509.00 in company stock.Percentage Held by Insiders14.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Progyny are expected to grow by 25.93% in the coming year, from $0.54 to $0.68 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Progyny is 70.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Progyny is 70.24, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.05.Price to Earnings Growth RatioProgyny has a PEG Ratio of 1.54. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioProgyny has a P/B Ratio of 8.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Progyny (NASDAQ:PGNY) StockProgyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Read More PGNY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PGNY Stock News HeadlinesSeptember 28, 2023 | nasdaq.comCanaccord Genuity Initiates Coverage of Progyny (PGNY) with Buy RecommendationSeptember 27, 2023 | finance.yahoo.comProgyny (PGNY): Unveiling Its True ValueSeptember 29, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! September 13, 2023 | benzinga.comCheck Out What Whales Are Doing With PGNYSeptember 1, 2023 | finance.yahoo.com3 Reasons Growth Investors Will Love Progyny (PGNY)August 29, 2023 | msn.comWall Street Loves These 3 Growth Stocks; Should You?August 22, 2023 | finance.yahoo.comProgyny Celebrates More Than 30,000 Amazonians Supported on Their Family Building JourneysAugust 21, 2023 | seekingalpha.comProgyny: Strong Secular Tailwind, Great Performance, Recommend LongSeptember 29, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! August 16, 2023 | finance.yahoo.comHere is Why Growth Investors Should Buy Progyny (PGNY) NowAugust 16, 2023 | finance.yahoo.comHere’s Why Progyny (PGNY) Outperformed in Q2August 11, 2023 | finance.yahoo.comProgyny (PGNY) Upgraded to Buy: What Does It Mean for the Stock?August 10, 2023 | finance.yahoo.comTPG GP A, LLC Reduces Stake in Progyny IncAugust 7, 2023 | bizjournals.comFertility benefits management company Progyny expands to offer menopause careAugust 7, 2023 | markets.businessinsider.comTruist Financial Sticks to Their Buy Rating for Progyny (PGNY)August 5, 2023 | finance.yahoo.comIs There Now An Opportunity In Progyny, Inc. (NASDAQ:PGNY)?August 4, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for ProgynyAugust 4, 2023 | finance.yahoo.comProgyny Unveils Nationwide Access to Menopause CareAugust 4, 2023 | finance.yahoo.comCompared to Estimates, Progyny (PGNY) Q2 Earnings: A Look at Key MetricsAugust 3, 2023 | finance.yahoo.comProgyny, Inc. Announces Second Quarter 2023 ResultsAugust 3, 2023 | finance.yahoo.comProgyny (PGNY) Beats Q2 Earnings and Revenue EstimatesJuly 26, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Boston Scientific (BSX), Teladoc (TDOC) and Progyny (PGNY)July 20, 2023 | finance.yahoo.comProgyny, Inc. Announces Details for Its Second Quarter 2023 Results ReportJuly 19, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Progyny (PGNY)July 18, 2023 | finance.yahoo.comProgyny (NASDAQ:PGNY) grows 4.8% this week, taking three-year gains to 54%July 7, 2023 | msn.comWhat Makes Progyny (PGNY) a New Buy StockJune 29, 2023 | finance.yahoo.comQuantum Health Partners With Progyny To Launch New Family-Building Benefits OfferingSee More Headlines Receive PGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter. Email Address PGNY Company Calendar Last Earnings8/03/2023Today9/29/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PGNY CUSIPN/A CIK1551306 Webwww.progyny.com Phone212-888-3124FaxN/AEmployees393Year Founded2008Price Target and Rating Average Stock Price Forecast$48.67 High Stock Price Forecast$62.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+41.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.49 Trailing P/E Ratio70.18 Forward P/E Ratio63.69 P/E Growth1.52Net Income$30.36 million Net Margins5.15% Pretax Margin5.14% Return on Equity12.19% Return on Assets8.27% Debt Debt-to-Equity RatioN/A Current Ratio2.89 Quick Ratio2.89 Sales & Book Value Annual Sales$786.91 million Price / Sales4.17 Cash Flow$0.35 per share Price / Cash Flow99.43 Book Value$4.06 per share Price / Book8.47Miscellaneous Outstanding Shares95,410,000Free Float81,763,000Market Cap$3.28 billion OptionableNot Optionable Beta1.51 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David J. Schlanger (Age 64)Exec. Chairman Comp: $510.41kMr. Peter Anevski (Age 56)CEO & Director Comp: $1.01MMr. Michael Sturmer (Age 46)Pres Comp: $761.5kMr. Mark S. Livingston (Age 57)Chief Financial Officer Comp: $693.87kMs. Allison Swartz (Age 33)Exec. VP, Gen. Counsel & Sec. Comp: $173.35kMr. James HartVP of Investor RelationsMs. Risa FisherExec. VP & Chief Marketing OfficerMs. Cassandra PrattSr. VP of PeopleMs. Julie StadlbauerExec. VP of Strategic Sales & PartnershipsMs. Janet Choi M.D.Member of the Medical Advisory Board & Chief Medical OfficerMore ExecutivesKey CompetitorsSotera HealthNASDAQ:SHCagilon healthNYSE:AGLDaVitaNYSE:DVAFresenius Medical Care AG & Co. KGaANYSE:FMSSelect MedicalNYSE:SEMView All CompetitorsInsiders & InstitutionsBarclays PLCBought 7,065 shares on 9/21/2023Ownership: 0.065%Portside Wealth Group LLCBought 86,738 shares on 9/1/2023Ownership: 0.091%California State Teachers Retirement SystemBought 3,285 shares on 8/21/2023Ownership: 0.101%Osaic Holdings Inc.Bought 1,136 shares on 8/21/2023Ownership: 0.050%Teachers Retirement System of The State of KentuckyBought 1,229 shares on 8/21/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions PGNY Stock - Frequently Asked Questions Should I buy or sell Progyny stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PGNY shares. View PGNY analyst ratings or view top-rated stocks. What is Progyny's stock price forecast for 2023? 8 equities research analysts have issued 12-month price targets for Progyny's stock. Their PGNY share price forecasts range from $34.00 to $62.00. On average, they predict the company's stock price to reach $48.67 in the next year. This suggests a possible upside of 41.5% from the stock's current price. View analysts price targets for PGNY or view top-rated stocks among Wall Street analysts. How have PGNY shares performed in 2023? Progyny's stock was trading at $31.15 at the start of the year. Since then, PGNY stock has increased by 10.4% and is now trading at $34.39. View the best growth stocks for 2023 here. When is Progyny's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our PGNY earnings forecast. How were Progyny's earnings last quarter? Progyny, Inc. (NASDAQ:PGNY) announced its quarterly earnings results on Thursday, August, 3rd. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.10 by $0.05. The firm earned $279.40 million during the quarter, compared to the consensus estimate of $261.91 million. Progyny had a trailing twelve-month return on equity of 12.19% and a net margin of 5.15%. Progyny's quarterly revenue was up 43.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.09 earnings per share. What ETFs hold Progyny's stock? ETFs with the largest weight of Progyny (NASDAQ:PGNY) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), Aztlan Global Stock Selection DM SMID ETF (AZTD), BNY Mellon Women's Opportunities ETF (BKWO), SPDR S&P Health Care Services ETF (XHS), Thrivent Small-Mid Cap ESG ETF (TSME), Harbor Corporate Culture Small Cap ETF (HAPS), Nuveen Small Cap Select ETF (NSCS) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has Progyny issued on next quarter's earnings? Progyny updated its FY23 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of $0.50-$0.53 for the period, compared to the consensus earnings per share estimate of $0.47. The company issued revenue guidance of $1.075-$1.09 billion, compared to the consensus revenue estimate of $1.06 billion. What is David Schlanger's approval rating as Progyny's CEO? 25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees. What other stocks do shareholders of Progyny own? Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD). When did Progyny IPO? (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers. What is Progyny's stock symbol? Progyny trades on the NASDAQ under the ticker symbol "PGNY." How do I buy shares of Progyny? Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Progyny's stock price today? One share of PGNY stock can currently be purchased for approximately $34.39. How much money does Progyny make? Progyny (NASDAQ:PGNY) has a market capitalization of $3.28 billion and generates $786.91 million in revenue each year. The company earns $30.36 million in net income (profit) each year or $0.49 on an earnings per share basis. How many employees does Progyny have? The company employs 393 workers across the globe. How can I contact Progyny? Progyny's mailing address is 1359 BROADWAY, NEW YORK NY, 10018. The official website for the company is www.progyny.com. The company can be reached via phone at 212-888-3124 or via email at investors@progyny.com. This page (NASDAQ:PGNY) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.